CA3196146A1 - Compounds and methods for the treatment of ocular disorders - Google Patents

Compounds and methods for the treatment of ocular disorders

Info

Publication number
CA3196146A1
CA3196146A1 CA3196146A CA3196146A CA3196146A1 CA 3196146 A1 CA3196146 A1 CA 3196146A1 CA 3196146 A CA3196146 A CA 3196146A CA 3196146 A CA3196146 A CA 3196146A CA 3196146 A1 CA3196146 A1 CA 3196146A1
Authority
CA
Canada
Prior art keywords
radical
substituted
alkyl
compound
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3196146A
Other languages
English (en)
French (fr)
Inventor
Charles Bosworth
Mark Richard Stewart
Hila Barash
Nicholas Andrew CHAPMAN
Robert M. Burk
Ian Holmes
Marc GLEESON
Yair Alster
Omer Rafaeli
Jonathan DUNN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azura Ophthalmics Ltd
Original Assignee
Azura Ophthalmics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azura Ophthalmics Ltd filed Critical Azura Ophthalmics Ltd
Publication of CA3196146A1 publication Critical patent/CA3196146A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3196146A 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders Pending CA3196146A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094808P 2020-10-21 2020-10-21
US63/094,808 2020-10-21
PCT/IB2021/000708 WO2022084739A1 (en) 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
CA3196146A1 true CA3196146A1 (en) 2022-04-28

Family

ID=81290138

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3196146A Pending CA3196146A1 (en) 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders

Country Status (10)

Country Link
US (1) US20230399317A1 (cg-RX-API-DMAC10.html)
EP (1) EP4232034A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023546452A (cg-RX-API-DMAC10.html)
KR (1) KR20230110516A (cg-RX-API-DMAC10.html)
CN (1) CN116635032A (cg-RX-API-DMAC10.html)
AU (1) AU2021365530A1 (cg-RX-API-DMAC10.html)
CA (1) CA3196146A1 (cg-RX-API-DMAC10.html)
IL (1) IL302174A (cg-RX-API-DMAC10.html)
MX (1) MX2023004538A (cg-RX-API-DMAC10.html)
WO (1) WO2022084739A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
WO2024100454A2 (en) * 2022-11-11 2024-05-16 Azura Ophthalmics Ltd. Composition and methods for improving signs and symptoms of ocular disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702984C (en) * 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
EP3827823A1 (en) * 2012-12-19 2021-06-02 Novartis AG Lfa-1 inhibitor formulations
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
WO2017055924A2 (en) * 2015-09-28 2017-04-06 M.G. Therapeutics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
CA3020713A1 (en) * 2016-04-19 2017-10-26 Azura Ophthalmics Ltd. Compositions for the treatment of hyperkeratosis disorders
CA3057569A1 (en) * 2017-03-29 2018-10-04 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
US20180333357A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Nanoemulsions with anti-inflammatory activity
WO2019053607A1 (en) * 2017-09-18 2019-03-21 Glenmark Pharmaceuticals Limited PROCESS FOR PREPARING LIFITEGRAST
WO2019096996A1 (en) * 2017-11-17 2019-05-23 Medichem, S.A. A process to obtain a tetrahydroisoquinoline derivative
WO2020212755A1 (en) * 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Also Published As

Publication number Publication date
EP4232034A1 (en) 2023-08-30
CN116635032A (zh) 2023-08-22
US20230399317A1 (en) 2023-12-14
KR20230110516A (ko) 2023-07-24
IL302174A (en) 2023-06-01
AU2021365530A1 (en) 2023-06-15
AU2021365530A9 (en) 2024-02-08
JP2023546452A (ja) 2023-11-02
EP4232034A4 (en) 2024-12-04
MX2023004538A (es) 2023-06-19
WO2022084739A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
US11643429B2 (en) Compounds and methods for the treatment of ocular disorders
US10875845B2 (en) Compounds and methods for the treatment of ocular disorders
CA3196145A1 (en) Compounds and methods for the treatment of ocular disorders
EP4232458A1 (en) Compounds and methods for the treatment of ocular disorders
AU2021365530A9 (en) Compounds and methods for the treatment of ocular disorders
US20250042931A1 (en) Compounds and methods for the treatment of ocular disorders
WO2024134272A2 (en) Compounds and methods for the treatment of dermal and ocular disorders
CA3234228A1 (en) Compounds and methods for the treatment of dermal and ocular disorders
CN116940570A (zh) 用于治疗眼部病症的化合物和方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241011

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241011

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251222

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260420

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428